 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
| |

|
|
|
|
|
SAN FRANCISCO, CA – June, 2013 — Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors. |
|
|
SAN FRANCISCO, CA – January 23, 2013 — Celtaxsys, Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced the appointments of Edward E. Philpot, M.D, J. Stuart Elborn, M.D., Richard B. Moss, M.D., Steven M. Rowe, M.D., M.S.P.H., and Michael S. Schechter, M.D., M.P.H., to its new Medical Advisory Panel. |
|
|
SAN FRANCISCO, CA – January 3, 2013 - Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H). |
|
|
SAN FRANCISCO, October 23rd, 2012 -- Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, today announced the appointment of life sciences technology expert, Brett A. Premack, Ph.D., as Chief Technology Officer.
|
|
|
San Francisco, Calif., January 5, 2012 /PRNewswire / -- Celtaxsys, Inc. a privately held biotechnology company announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.
|
|
|
SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD). |
|
|
ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors |
|
| |
|
|
|
|
|
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
 |
Copyright © 2013 Celtaxsys, Inc., San Francisco, CA
|
|
|